A critical appraisal of platelet glycoprotein IIb/IIIa inhibition (Q34111637)

31 July 2017

1 reference

title

A critical appraisal of platelet glycoprotein IIb/IIIa inhibition (English)

1 reference

31 July 2017

D P Chew

1

1 reference

31 July 2017

D J Moliterno

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

Journal of the American College of Cardiology

31 July 2017

published in

1 reference

31 July 2017

volume

36

1 reference

31 July 2017

issue

7

1 reference

31 July 2017

page(s)

2028-2035

1 reference

Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Peptide ligands can bind to distinct sites in integrin alphaIIbbeta3 and elicit different functional responses

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Perspectives series: cell adhesion in vascular biology. Integrin signaling in vascular biology

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa).

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Activation of alphaVbeta3 on vascular cells controls recognition of prothrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Potential non-glycoprotein IIb/IIIa effects of abciximab

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Altered platelet function detected by flow cytometry. Effects of coronary artery disease and age.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Evidence for abnormal platelet glycoprotein expression in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Expression of Markers of Platelet Activation and the Interpatient Variation in Response to Abciximab

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

RGD peptides induce apoptosis by direct caspase-3 activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Clinical pharmacology of eptifibatide

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900979-7

7 January 2021

10.1016/S0735-1097(00)00979-7

Identifiers

DOI

1 reference

31 July 2017

1 reference